Category

Daily Briefs

Daily Brief Consumer: Lifedrink , BYD, Alibaba, KT&G Corporation, Golden Throat Holdings, Orion Breweries Limited, Genting Bhd, PDD Holdings and more

By | Consumer, Daily Briefs

In today’s briefing:

  • [Japan ECM] Lifedrink (2585) – Fast-Growing Beverage Seller Meets P.E. Firm Selldown
  • BYD (1211 HK): Flat Sales Volume in August and Lower Margin in 1H25
  • Cheap Vs. Rich Volatility: What Cones Reveal in Tencent, HSBC, Meituan & More
  • KT&G: Selling 57 Real Estate Properties to Generate 1 Trillion Won in Additional Cash Flow
  • Lifedrink Placement: Cleanup Sale but Placement Properties Are Not Great
  • Golden Throat (6896 HK): China’s Leading Lozenge Maker at 10x P/E and a 10% Dividend Yield
  • Orion Breweries IPO – Smaller Scale Warrants Discount
  • Genting Berhad – Earnings Flash – H1 FY 2025 Results – Lucror Analytics
  • Pinduoduo’s Growth Slows as Competition, Tariffs Hit Temu Expansion
  • Orion Breweries IPO: Turning Local Strength into Growth Abroad


[Japan ECM] Lifedrink (2585) – Fast-Growing Beverage Seller Meets P.E. Firm Selldown

By Travis Lundy

  • Today post-close, Lifedrink (2585 JP) announced the Sunrise PE funds which own 22% of the company will sell their stake in a clean-up offering with pricing in 8 days.
  • This offering comes 8 trading days after a new post-earnings all-time-high. At 24x ADV, the offering will increase Max Real World Float by 50+%. 
  • There are some index and buyback supply/demand dynamics to note. It’s a heavy offering, so bullish/bearish may be a matter of horizon.

BYD (1211 HK): Flat Sales Volume in August and Lower Margin in 1H25

By Ming Lu

  • In August, BYD’s total sales volume was still flat and its domestic sales volume continued to shrink.
  • The operating margin declined significantly to 2.3% in 1H25 from 4.4% in 1H24.
  • The P/E band suggests a downside of 23% and a price target of HK$89.00.

Cheap Vs. Rich Volatility: What Cones Reveal in Tencent, HSBC, Meituan & More

By Gaudenz Schneider

  • Context: Volatility cones provide a clear framework to evaluate whether options are trading cheap or rich.
  • Highlights:Tencent (700 HK), HSBC (5 HK),Meituan (3690 HK), Ping An (2318 HK), and JD.com (9618 HK) all display historically cheap implied volatility. Read on for trade suggestions.
  • Why Read: Spot opportunities, assess regime shifts, and manage risk effectively — volatility cones turn complex data into actionable insights for traders and investors.

KT&G: Selling 57 Real Estate Properties to Generate 1 Trillion Won in Additional Cash Flow

By Douglas Kim

  • KT&G announced that it is selling numerous properties nationwide as well as financial assets, aiming to generate about 1 trillion won in additional cash flow.
  • KT&G has started to sell off a number of real estate properties in Seoul, Bundang, Daegu, Sejong, Busan, and North Chungcheong, and other parts of Korea through public bidding process.
  • Four key catalysts with KT&G include an increasing probability of cigarette price hike, asset sales of non-core properties/improving corporate governance, high dividend yields, and profitable growth of core tobacco business. 

Lifedrink Placement: Cleanup Sale but Placement Properties Are Not Great

By Nicholas Tan

  • Lifedrink (2585 JP)  is looking to raise around US$175m from a secondary placement.
  • The deal is a large one to digest, representing 20.7 days of the stock’s three month ADV, despite being 18.4% of total shares outstanding.
  • In this note, we will talk about the placement and run the deal through our ECM framework.

Golden Throat (6896 HK): China’s Leading Lozenge Maker at 10x P/E and a 10% Dividend Yield

By Michael Fritzell

  • Golden Throat (6896 HK — US$343 million) is an iconic Chinese brand of throat lozenges, used to deal with sore or dry throats.

  • The core product is similar to Strepsils, Halls, or Ricola, but is sold over-the-counter in pharmacies.

  • The company sells 146 million boxes per year and has an estimated market share of 26% in China.


Orion Breweries IPO – Smaller Scale Warrants Discount

By Akshat Shah

  • Orion Breweries Limited’s (409A JT) operations span across alcoholic beverages, tourism and hotel businesses, aiming to raise ~US$126m in its Japan IPO via a mix of primary and secondary offerings.
  • Orion Breweries (OBL) has a strong Okinawa market position. Share of overseas sales has been growing (~23% of FY25 revenues), while profitability has also largely been steady.
  • In our previous note, we looked at the firm’s past performance. In this note, we talk about the peer comparison and IPO valuations.

Genting Berhad – Earnings Flash – H1 FY 2025 Results – Lucror Analytics

By Leonard Law, CFA

  • Genting Berhad’s H1/25 results were soft.
  • Revenue and EBITDA picked up q-o-q in Q2, albeit the numbers were down on a y-o-y basis.
  • The group reported sound earnings growth from Genting Malaysia (supported by improved gaming volumes at Resorts World Genting), though they were offset by earnings declines from Resorts World Singapore and the US assets.

Pinduoduo’s Growth Slows as Competition, Tariffs Hit Temu Expansion

By Caixin Global

  • Pinduoduo Holdings Inc. on Monday reported its slowest revenue growth in three years, as the Chinese e-commerce giant ran into stiffer competition at home and new tariff challenges abroad for its overseas arm Temu.
  • The Nasdaq-listed company posted second-quarter revenue of 103.99 billion yuan ($14.5billion), just above market expectations and up 7% from a year earlier. That marked the fifth straight quarter of deceleration and the slowest pace since mid-2022.
  • Pinduoduo’s meteoric rise since launching Temu in September 2022 peaked with a 131% revenue surge in the first quarter of 2024. Growth has slowed each quarter since, falling to 86% in the second quarter of 2024, 44% in the third, 24% in the fourth, and only 10% in the first quarter of 2025.

Orion Breweries IPO: Turning Local Strength into Growth Abroad

By Oshadhi Kumarasiri

  • Orion Breweries Limited (409A JT) has become synonymous with Okinawa, combining heritage, loyalty, and local identity into a brand experience that larger rivals struggle to replicate.
  • The company benefits from Okinawa’s nearly 10 million annual visitors, turning tourism into both a sales driver and a powerful channel for brand amplification abroad.
  • The IPO offers attractive valuation versus peers, despite risks from MBO-related debt and potential share overhang from private equity owners.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Quantitative Analysis: Hong Kong Connect Flows (August): $18bn Inflows and more

By | Daily Briefs, Quantitative Analysis

In today’s briefing:

  • Hong Kong Connect Flows (August): $18bn Inflows
  • HSCEI Index Earning Revision (Aug): BIDU, China Life, JD.COM, BEIGENE, MEITUAN, Sinopec, China Life
  • HS TECH Index Earning Revision (Aug): NTES, LI AUTO, BIDU, HORIZON ROBOTICS, MEITUAN, JD.COM
  • HSI Index Earning Revision (Aug): AIA, HSBC, MEITUAN, JD.COM, BIDU, SINO BIOPHARM


Hong Kong Connect Flows (August): $18bn Inflows

By Ke Yan, CFA, FRM

  • We analyze the monthly Hong Kong Connect flows with our data engine.
  • We tabulate the top stocks by inflows, outflows, and holding by mainland investors.
  • We highlight flows of Alibaba, Tencent, Meituan, China Life, HSTECH ETF.

HSCEI Index Earning Revision (Aug): BIDU, China Life, JD.COM, BEIGENE, MEITUAN, Sinopec, China Life

By Ke Yan, CFA, FRM

  • We analysed the earning revision of component stocks of HSCEI in the past month.
  • We tabulated stocks with the top impact on index’s EPS, stocks’ EPS revision, and revenue revision.
  • We highlighted EPS revision on BIDU, China Life, JD.COM, BEIGENE, MEITUAN, Sinopec, China Life, Beigene, Meituan, Jd, Bidu, Sinopec.

HS TECH Index Earning Revision (Aug): NTES, LI AUTO, BIDU, HORIZON ROBOTICS, MEITUAN, JD.COM

By Ke Yan, CFA, FRM

  • We analysed the earning revision of component stocks of HS TECH in the past month.
  • We tabulated stocks with the top impact on index’s EPS, stocks’ EPS revision, and revenue revision.
  • We highlighted EPS revision on NTES, LI AUTO, BIDU, HORIZON ROBOTICS, MEITUAN, JD.COM, Meituan, Jd, Bidu, Ntes, Li Auto, Horizonrobot.

HSI Index Earning Revision (Aug): AIA, HSBC, MEITUAN, JD.COM, BIDU, SINO BIOPHARM

By Ke Yan, CFA, FRM

  • We analysed the earning revision of component stocks of HSI in the past month.
  • We tabulated stocks with the top impact on index’s EPS, stocks’ EPS revision, and revenue revision.
  • We highlighted EPS revision on AIA, HSBC, MEITUAN, JD.COM, BIDU, SINO BIOPHARM, XINYI SOLAR, HSBC, Meituan, Jd, AIA, Bidu, Sino Biopharm, Xinyi Solar.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Thematic (Sector/Industry): Ohayo Japan | Defence Shares Lead EU Gains; US Closed and more

By | Daily Briefs, Thematic (Sector/Industry)

In today’s briefing:

  • Ohayo Japan | Defence Shares Lead EU Gains; US Closed
  • Singapore Fintech Sector: Good Potential but a Few SGX Listings Thus Far
  • Thematic Report: India’s Economy Remain Resilient During Uncertain Times
  • Exencial Industry Tidings 01/09/2025


Ohayo Japan | Defence Shares Lead EU Gains; US Closed

By Mark Chadwick

  • US stocks and Treasuries were closed for the Labor Day holiday; US stock futures rebounded 0.2%
  • In Europe, defense shares led gains, with BAE Systems and Rheinmetall surging after reports of European plans for post-conflict deployments in Ukraine
  • Niterra agreed to acquire Denso’s automotive plug business for 180 billion yen

Singapore Fintech Sector: Good Potential but a Few SGX Listings Thus Far

By Wealth Management Alliance

  • The global fintech industry has had a long history but momentum gathered pace only with the advent of smartphones in the 1990s and modern artificial intelligence in the 2010s. Current market size is estimated at around USD320bn.
  • Singapore’s fintech industry took off in the 2010s with the support of government initiatives. Depending on definition and scope, there is a wide range in the estimated size of the industry in Singapore, but likely to be in the range of USD10-30bn. Importantly, industry projections point to double-digit annual growth in the coming years.
  • The key players in the Singapore fintech sector include traditional and digital banks, an array of private companies, and a handful of SGX listed counters.

Thematic Report: India’s Economy Remain Resilient During Uncertain Times

By Nimish Maheshwari

  • India’s National Statistical Office reported 7.8% real GDP growth for Q1 FY26 (Apr–Jun 2025), a clear beat versus a Reuters poll at 6.7% and above Q4’s 7.4%
  • Economists point to a softer deflator, solid government capex, and front-loaded exports ahead of tariff implementation. Even so, the level of real activity was strong relative to expectations. 
  • Strong domestic parameters like GST and PMI, points towards strong domestic demand despite tariff and export uncertainty.

Exencial Industry Tidings 01/09/2025

By Viral Kishorchandra Shah

  • IMD predicts crop damage due to above-normal rains in Sept 2025
  • Tea prices in auction centers across India fall 13% in August 2025
  • Russia boosts fertiliser exports to India by 20% in January-June 2025

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief ESG: Continuing Parent-Subsidiary Listings Is Losing Value that Could Be Reliably Obtained and more

By | Daily Briefs, ESG

In today’s briefing:

  • Continuing Parent-Subsidiary Listings Is Losing Value that Could Be Reliably Obtained


Continuing Parent-Subsidiary Listings Is Losing Value that Could Be Reliably Obtained

By Aki Matsumoto

  • Listed subsidiaries focusing on core businesses have higher capital profitability and stock valuations than parent companies, while parent companies with diversified businesses have lower than listed subsidiaries in the both.
  • By converting a listed subsidiary with high capital profitability into a wholly owned subsidiary, or by selling a listed subsidiary with low capital profitability,  it could increase profitability of parent.
  • Even though this was expected, parent-subsidiary listings continue to this day (recently, more subsidiaries are listing on Standard Market), and the value that can be reliably obtained is being lost.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Australia: Mayne Pharma, Apiam Animal Health, Lynas Corp Ltd, Neuren Pharmaceuticals, Iron Ore, Kinatico and more

By | Australia, Daily Briefs

In today’s briefing:

  • Mayne Pharma (MYX AU): FY25 Results Aid Both Sides
  • Current Merger Arbitrage Opportunities and Strategic Reviews in Global Markets: Key Active Cases
  • Lynas (LYC AU) Targets Vertical Expansion
  • Merger Arbitrage Opportunities and Strategic Updates: AHX, PLYM, LWAY, YORKU, NZM, PAC and More
  • Apiam Animal Health Receives A$0.88/Share Takeover Offer from Adamantem Capital
  • Neuren Pharmaceuticals (NEU AU): Net Profit Doubles in 1H On Daybue Acceleration; Guidance Restated
  • Fenix Resources (FEX AU): Exciting Value-Adding Catalyst Can Triple Production Again
  • Kinatico Ltd – Record profits, RaaS forecasts beat


Mayne Pharma (MYX AU): FY25 Results Aid Both Sides

By Arun George

  • On 29 August, Mayne Pharma (MYX AU) reported its FY25 results with underlying EBITDA of A$47 million, which is at the lower end of its guidance range. 
  • At first glance, FY25 results are positive for Mayne as they suggest that the weak 3Q was an aberration and its performance is on an upward trajectory. 
  • However, my analysis suggests that the results provide Cosette with several angles to pursue to bolster its case of a MAC breach. This remains a high-risk/high-reward set-up. 

Current Merger Arbitrage Opportunities and Strategic Reviews in Global Markets: Key Active Cases

By Special Situation Investments

  • Apiam Animal Health received a takeover offer at A$0.88/share with an 11% spread, supported by founder Dr. Chris Richards.
  • Plymouth Industrial REIT has a $24.10/share bid from Sixth Street Capital, with a 14-15% spread and board review ongoing.
  • DallasNews has two takeover offers: $15/share from Hearst and $18.5/share from Alden, requiring two-thirds shareholder approval.

Lynas (LYC AU) Targets Vertical Expansion

By David Blennerhassett

  • Last week, rare-earth play Lynas Corp Ltd (LYC AU) squared away a fully underwritten A$750mn placement (56.6mn shares, 6.1% of shares outstanding) at A$13.25/share, a 10% discount to last close. 
  • Gina Rinehart, Lynas’ second largest shareholders with ~8.2%, took up her compliment. 
  • Placement proceeds will be applied to streamlining ops, expanding its stockpiles/capacity, and investing downstream into magnet makers.

Merger Arbitrage Opportunities and Strategic Updates: AHX, PLYM, LWAY, YORKU, NZM, PAC and More

By Special Situation Investments

  • Apiam Animal Health received a takeover offer from Adamantem Capital at A$0.88/share, with a current spread of 11%.
  • YORK announced a merger with CRO token issuance, with each YORK share representing approximately 47 CRO tokens.
  • Pacific Current Group’s FY25 results show a 28% discount to NAV, with potential capital allocation concerns.

Apiam Animal Health Receives A$0.88/Share Takeover Offer from Adamantem Capital

By Special Situation Investments

  • Apiam Animal Health received a takeover offer from Adamantem Capital at A$0.88/share, representing a 60% premium.
  • Adamantem has 30 days of exclusivity for due diligence, with support from AHX’s largest shareholder and founder.
  • AHX’s enterprise value is A$220m, aligning with Adamantem’s typical transaction size and strategic acquisition interests.

Neuren Pharmaceuticals (NEU AU): Net Profit Doubles in 1H On Daybue Acceleration; Guidance Restated

By Tina Banerjee

  • Neuren Pharmaceuticals (NEU AU) announced stellar financial performance for 1H25, with doubling of net profit on high-teens revenue growth. Royalty income from Daybue grew 16% YoY to A$28.3M.
  • The number of unique patients receiving a Daybue shipment continued to grow and in 2Q25 reached a record high of 987, up from 954 in 1Q25 and 920 in 4Q24.
  • Assuming partner’s guidance is met and an exchange rate of 0.65, Neuren anticipates earning U.S. royalties of A$62–67M, up 15% YoY at mid-point in 2025.

Fenix Resources (FEX AU): Exciting Value-Adding Catalyst Can Triple Production Again

By Sameer Taneja

  • Fenix Resources (FEX AU) has secured an exclusive 30-year mining right to the Weld Range Project, which has 290 million tons of resource and will significantly extend Fenix’s mine life.
  • Initial plans are to increase production from the Weld Range to 6 million tons, taking Fenix Resources (FEX AU) to a 10-12 million ton production profile. 
  • Fenix Resources (FEX AU) has already nearly tripled its production from 1.5 million tonnes to 4.4 million tonnes and trades at a 1.7x price-to-OCF (at a $100/tonne iron ore price). 

Kinatico Ltd – Record profits, RaaS forecasts beat

By Research as a Service (RaaS)

  • Kinatico Ltd (ASX:KYP) is a ‘Know Your People’ regtech company providing workforce compliance monitoring and management technology and services.
  • The company has reported a 50% increase in FY25 adjusted NPAT to $1.5m, almost 30% ahead of our forecast for the year.
  • Adjusted EBITDA for the year was $4.7m, up 21% on the previous corresponding period (pcp) on the previously reported 12% increase in revenue to $32.1m.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Event-Driven: Mayne Pharma (MYX AU): FY25 Results Aid Both Sides and more

By | Daily Briefs, Event-Driven

In today’s briefing:

  • Mayne Pharma (MYX AU): FY25 Results Aid Both Sides
  • HKBN (1310 HK): On the Cusp of Being Declared Unconditional
  • Clearing up the FSS’s Sudden Call on Samsung Life’s Samsung Elec Stake Accounting Shift
  • Current Merger Arbitrage Opportunities and Strategic Reviews in Global Markets: Key Active Cases
  • A/H Premium Tracker (To 29 Aug 2025):  AH Premia Expand Again, Beautiful Skew Takes a Breather
  • Lynas (LYC AU) Targets Vertical Expansion
  • Huaxin Cement (6655 HK): Floats Non-Chinese Ops Spin-Off
  • Increasing Probability of Hanwha Group Selling Its 8% Stake in Korea Zinc
  • Merger Arbitrage Opportunities and Strategic Updates: AHX, PLYM, LWAY, YORKU, NZM, PAC and More
  • Apiam Animal Health Receives A$0.88/Share Takeover Offer from Adamantem Capital


Mayne Pharma (MYX AU): FY25 Results Aid Both Sides

By Arun George

  • On 29 August, Mayne Pharma (MYX AU) reported its FY25 results with underlying EBITDA of A$47 million, which is at the lower end of its guidance range. 
  • At first glance, FY25 results are positive for Mayne as they suggest that the weak 3Q was an aberration and its performance is on an upward trajectory. 
  • However, my analysis suggests that the results provide Cosette with several angles to pursue to bolster its case of a MAC breach. This remains a high-risk/high-reward set-up. 

HKBN (1310 HK): On the Cusp of Being Declared Unconditional

By Arun George

  • HKBN Ltd (1310 HK)’s offer from China Mobile (941 HK) is HK$5.075 with a 50% minimum acceptance condition. The first closing date is September 3.
  • Based on CCASS data, including acceptances, China Mobile’s shareholding was 48.93% of outstanding shares as of September 1.
  • Therefore, the offer should be declared unconditional by the first closing date. At the last close and for a September 12 payment, the gross/annualised spread is 0.5%/15.7%.

Clearing up the FSS’s Sudden Call on Samsung Life’s Samsung Elec Stake Accounting Shift

By Sanghyun Park

  • Today’s FSS IFRS17 ruling is an accounting fix (equity vs. liability), not the Samsung Life Law, which is a regulatory cap on affiliate stakes based on market value.
  • The FSS ruling signals Samsung Life doesn’t need to treat its Samsung Electronics stake as a forced-sale liability, lowering near-term sale risk.
  • This eases the overhang, delays potential stake moves, and reinforces the relative underperformance setup on Samsung C&T highlighted in earlier posts.

Current Merger Arbitrage Opportunities and Strategic Reviews in Global Markets: Key Active Cases

By Special Situation Investments

  • Apiam Animal Health received a takeover offer at A$0.88/share with an 11% spread, supported by founder Dr. Chris Richards.
  • Plymouth Industrial REIT has a $24.10/share bid from Sixth Street Capital, with a 14-15% spread and board review ongoing.
  • DallasNews has two takeover offers: $15/share from Hearst and $18.5/share from Alden, requiring two-thirds shareholder approval.

A/H Premium Tracker (To 29 Aug 2025):  AH Premia Expand Again, Beautiful Skew Takes a Breather

By Travis Lundy

  • HUGE, rampaging, “Beautiful Skew”… is flat. Big swings in H/A ratios continue, this time on average with 2.1% H underperformance vs As which is -4.4% on average over two weeks.
  • Last week’s short reco on Fuyao Glass Industry Group (3606 HK) was up 2.3% on the week in Hs but Hs underperformed the As by 1.86%.
  • AH premia are in a widening phase. This may continue. New reco this week.

Lynas (LYC AU) Targets Vertical Expansion

By David Blennerhassett

  • Last week, rare-earth play Lynas Corp Ltd (LYC AU) squared away a fully underwritten A$750mn placement (56.6mn shares, 6.1% of shares outstanding) at A$13.25/share, a 10% discount to last close. 
  • Gina Rinehart, Lynas’ second largest shareholders with ~8.2%, took up her compliment. 
  • Placement proceeds will be applied to streamlining ops, expanding its stockpiles/capacity, and investing downstream into magnet makers.

Huaxin Cement (6655 HK): Floats Non-Chinese Ops Spin-Off

By David Blennerhassett

  • Two days after announcing its 2025 interims, Holcim (HOLN SW)-backed Huaxin Cement (6655 HK) proposed spinning off its overseas cement assets.
  • The overseas ops, predominantly located in Africa, significantly outperformed the PRC ops in FY24, a trend that continued into 2025. 
  • No preferred bourse was stipulated, although the HKEx appears the logical choice. Pegged to historical trading metrics, Huaxin appears fully valued here.

Increasing Probability of Hanwha Group Selling Its 8% Stake in Korea Zinc

By Douglas Kim

  • There has been an increasing probability of the Hanwha Group selling its stake in Korea Zinc (010130 KS) mainly due to increasing burden of its petrochemical affiliates.
  • For now, the Hanwha Group has denied all news regarding its potential sale of stake in Korea Zinc.
  • In our view, the timing of this potential sale in Korea Zinc by Hanwha Group is less likely in 2025 but could occur in 2026/2027. 

Merger Arbitrage Opportunities and Strategic Updates: AHX, PLYM, LWAY, YORKU, NZM, PAC and More

By Special Situation Investments

  • Apiam Animal Health received a takeover offer from Adamantem Capital at A$0.88/share, with a current spread of 11%.
  • YORK announced a merger with CRO token issuance, with each YORK share representing approximately 47 CRO tokens.
  • Pacific Current Group’s FY25 results show a 28% discount to NAV, with potential capital allocation concerns.

Apiam Animal Health Receives A$0.88/Share Takeover Offer from Adamantem Capital

By Special Situation Investments

  • Apiam Animal Health received a takeover offer from Adamantem Capital at A$0.88/share, representing a 60% premium.
  • Adamantem has 30 days of exclusivity for due diligence, with support from AHX’s largest shareholder and founder.
  • AHX’s enterprise value is A$220m, aligning with Adamantem’s typical transaction size and strategic acquisition interests.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Credit: Genting Berhad – Earnings Flash – H1 FY 2025 Results – Lucror Analytics and more

By | Credit, Daily Briefs

In today’s briefing:

  • Genting Berhad – Earnings Flash – H1 FY 2025 Results – Lucror Analytics


Genting Berhad – Earnings Flash – H1 FY 2025 Results – Lucror Analytics

By Leonard Law, CFA

  • Genting Berhad’s H1/25 results were soft.
  • Revenue and EBITDA picked up q-o-q in Q2, albeit the numbers were down on a y-o-y basis.
  • The group reported sound earnings growth from Genting Malaysia (supported by improved gaming volumes at Resorts World Genting), though they were offset by earnings declines from Resorts World Singapore and the US assets.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief ECM: [Japan ECM] Lifedrink (2585) – Fast-Growing Beverage Seller Meets P.E. Firm Selldown and more

By | Daily Briefs, ECM

In today’s briefing:

  • [Japan ECM] Lifedrink (2585) – Fast-Growing Beverage Seller Meets P.E. Firm Selldown
  • Shandong Gold Mining Placement – H-Share Running Ahead of A-Shares
  • Simcere Pharma Placement – First Primary Raising, past Deals Have Been Mixed
  • Lifedrink Placement: Cleanup Sale but Placement Properties Are Not Great
  • Orion Breweries IPO – Smaller Scale Warrants Discount
  • Aux Electric IPO Trading: Decent Insti Demand; Is Cheap
  • Klarna IPO Valuation Update: $13B-$14B IPO Valuation Is Cheap Vs. Peers, ~68% Discount To Affirm
  • Orion Breweries IPO: Turning Local Strength into Growth Abroad


[Japan ECM] Lifedrink (2585) – Fast-Growing Beverage Seller Meets P.E. Firm Selldown

By Travis Lundy

  • Today post-close, Lifedrink (2585 JP) announced the Sunrise PE funds which own 22% of the company will sell their stake in a clean-up offering with pricing in 8 days.
  • This offering comes 8 trading days after a new post-earnings all-time-high. At 24x ADV, the offering will increase Max Real World Float by 50+%. 
  • There are some index and buyback supply/demand dynamics to note. It’s a heavy offering, so bullish/bearish may be a matter of horizon.

Shandong Gold Mining Placement – H-Share Running Ahead of A-Shares

By Sumeet Singh

  • Shandong Gold Mining (1787 HK) aims to raise around US$500m via a primary placement, in order to pay down debt.
  • The H-shares are now trading at all-time highs and have been performing better than the A-shares this year.
  • In this note, we talk about the deal dynamics and run the deal through our ECM framework.

Simcere Pharma Placement – First Primary Raising, past Deals Have Been Mixed

By Sumeet Singh

  • Simcere Pharmaceutical Group (2096 HK) is looking to raise around US$200m via a top-up placement.
  • This is the first primary raising by the company since its listing. There have been a few secondary deals, with mixed results.
  • In this note, we talk about the deal dynamics and run the deal through our ECM framework.

Lifedrink Placement: Cleanup Sale but Placement Properties Are Not Great

By Nicholas Tan

  • Lifedrink (2585 JP)  is looking to raise around US$175m from a secondary placement.
  • The deal is a large one to digest, representing 20.7 days of the stock’s three month ADV, despite being 18.4% of total shares outstanding.
  • In this note, we will talk about the placement and run the deal through our ECM framework.

Orion Breweries IPO – Smaller Scale Warrants Discount

By Akshat Shah

  • Orion Breweries Limited’s (409A JT) operations span across alcoholic beverages, tourism and hotel businesses, aiming to raise ~US$126m in its Japan IPO via a mix of primary and secondary offerings.
  • Orion Breweries (OBL) has a strong Okinawa market position. Share of overseas sales has been growing (~23% of FY25 revenues), while profitability has also largely been steady.
  • In our previous note, we looked at the firm’s past performance. In this note, we talk about the peer comparison and IPO valuations.

Aux Electric IPO Trading: Decent Insti Demand; Is Cheap

By Nicholas Tan

  • Aux Electric (2580 HK)  raised around US$532m in its Hong Kong IPO.
  • It is one of the global top five air conditioner providers. 
  • We have covered various aspects of the deal in our previous note. In this note, we will talk about the demand and trading dynamics.

Klarna IPO Valuation Update: $13B-$14B IPO Valuation Is Cheap Vs. Peers, ~68% Discount To Affirm

By Andrei Zakharov

  • Klarna Group plc, a first mover in the BNPL space and AI-powered fintech company, is targeting an IPO valuation of between $13B and $14B, according to Reuters.
  • A Swedish founder-led decacorn is preparing for a roadshow after Labor Day this week. They intend to raise up to ~$1B and start trading in September.
  • $13B-$14B IPO valuation is cheap vs. peers and implies ~68% discount to Affirm. Klarna’s last down round was a $800M venture round in July of 2022 at a ~$6.7B valuation.

Orion Breweries IPO: Turning Local Strength into Growth Abroad

By Oshadhi Kumarasiri

  • Orion Breweries Limited (409A JT) has become synonymous with Okinawa, combining heritage, loyalty, and local identity into a brand experience that larger rivals struggle to replicate.
  • The company benefits from Okinawa’s nearly 10 million annual visitors, turning tourism into both a sales driver and a powerful channel for brand amplification abroad.
  • The IPO offers attractive valuation versus peers, despite risks from MBO-related debt and potential share overhang from private equity owners.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief South Korea: Samsung Life Insurance, KT&G Corporation, Hanwha Solutions and more

By | Daily Briefs, South Korea

In today’s briefing:

  • Clearing up the FSS’s Sudden Call on Samsung Life’s Samsung Elec Stake Accounting Shift
  • KT&G: Selling 57 Real Estate Properties to Generate 1 Trillion Won in Additional Cash Flow
  • Increasing Probability of Hanwha Group Selling Its 8% Stake in Korea Zinc


Clearing up the FSS’s Sudden Call on Samsung Life’s Samsung Elec Stake Accounting Shift

By Sanghyun Park

  • Today’s FSS IFRS17 ruling is an accounting fix (equity vs. liability), not the Samsung Life Law, which is a regulatory cap on affiliate stakes based on market value.
  • The FSS ruling signals Samsung Life doesn’t need to treat its Samsung Electronics stake as a forced-sale liability, lowering near-term sale risk.
  • This eases the overhang, delays potential stake moves, and reinforces the relative underperformance setup on Samsung C&T highlighted in earlier posts.

KT&G: Selling 57 Real Estate Properties to Generate 1 Trillion Won in Additional Cash Flow

By Douglas Kim

  • KT&G announced that it is selling numerous properties nationwide as well as financial assets, aiming to generate about 1 trillion won in additional cash flow.
  • KT&G has started to sell off a number of real estate properties in Seoul, Bundang, Daegu, Sejong, Busan, and North Chungcheong, and other parts of Korea through public bidding process.
  • Four key catalysts with KT&G include an increasing probability of cigarette price hike, asset sales of non-core properties/improving corporate governance, high dividend yields, and profitable growth of core tobacco business. 

Increasing Probability of Hanwha Group Selling Its 8% Stake in Korea Zinc

By Douglas Kim

  • There has been an increasing probability of the Hanwha Group selling its stake in Korea Zinc (010130 KS) mainly due to increasing burden of its petrochemical affiliates.
  • For now, the Hanwha Group has denied all news regarding its potential sale of stake in Korea Zinc.
  • In our view, the timing of this potential sale in Korea Zinc by Hanwha Group is less likely in 2025 but could occur in 2026/2027. 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Most Read: Cambricon Technologies Lt, Yutaka Giken, Lifedrink , Dongfeng Motor, Mayne Pharma, Shandong Gold Mining , Simcere Pharmaceutical Group, HKBN Ltd, Apiam Animal Health, Samsung Life Insurance and more

By | Daily Briefs, Most Read

In today’s briefing:

  • STAR50/STAR100 Index Rebalance: Changes & Capping Lead to US$3.3bn Trade
  • [Japan M&A] Yutaka Giken (7229 JP) TOB – Possibly the Most Offensively Low TOB Price I’ve Ever Seen
  • [Japan ECM] Lifedrink (2585) – Fast-Growing Beverage Seller Meets P.E. Firm Selldown
  • Merger Arb Mondays (01 Sep) – Dongfeng, ENN, Joy City, Kangji, Mayne, Santos, Shibaura, CareNet
  • Mayne Pharma (MYX AU): FY25 Results Aid Both Sides
  • Shandong Gold Mining Placement – H-Share Running Ahead of A-Shares
  • Simcere Pharma Placement – First Primary Raising, past Deals Have Been Mixed
  • HKBN (1310 HK): On the Cusp of Being Declared Unconditional
  • Current Merger Arbitrage Opportunities and Strategic Reviews in Global Markets: Key Active Cases
  • Clearing up the FSS’s Sudden Call on Samsung Life’s Samsung Elec Stake Accounting Shift


STAR50/STAR100 Index Rebalance: Changes & Capping Lead to US$3.3bn Trade

By Brian Freitas

  • There is 1 constituent change for the STAR50 INDEX and 5 changes for the STAR100 Index at the next rebalance that will be implemented at the close on 12 September.
  • We estimate one-way turnover of 6.1% for the SSE STAR50 (STAR50 INDEX) resulting in a round-trip trade of CNY 23.8bn (US$3.3bn).
  • There will be huge capping outflows for Cambricon Technologies Lt (688256 CH) following the massive rally in the stock over the last couple of months.

[Japan M&A] Yutaka Giken (7229 JP) TOB – Possibly the Most Offensively Low TOB Price I’ve Ever Seen

By Travis Lundy

  • Honda Motor (7267 JP) and Samvardhana Motherson International Ltd (MOTHERSO IN) have arranged to buy Honda’s 69.7%-owned subsidiary Yutaka Giken (7229 JP) in a Tender Offer. 
  • The transaction structure means Motherson buys Yutaka for less than net cash but even assuming Motherson pay minority TOB price for everything, TOB ex-net cash = 0.05x PBR, <1x EBITDA.
  • But they are paying less. They are paying ¥12.4bn less than net cash, and getting the other ¥58bn of net assets (¥23bn inventory, the rest in hard assets) for free.

[Japan ECM] Lifedrink (2585) – Fast-Growing Beverage Seller Meets P.E. Firm Selldown

By Travis Lundy

  • Today post-close, Lifedrink (2585 JP) announced the Sunrise PE funds which own 22% of the company will sell their stake in a clean-up offering with pricing in 8 days.
  • This offering comes 8 trading days after a new post-earnings all-time-high. At 24x ADV, the offering will increase Max Real World Float by 50+%. 
  • There are some index and buyback supply/demand dynamics to note. It’s a heavy offering, so bullish/bearish may be a matter of horizon.


Mayne Pharma (MYX AU): FY25 Results Aid Both Sides

By Arun George

  • On 29 August, Mayne Pharma (MYX AU) reported its FY25 results with underlying EBITDA of A$47 million, which is at the lower end of its guidance range. 
  • At first glance, FY25 results are positive for Mayne as they suggest that the weak 3Q was an aberration and its performance is on an upward trajectory. 
  • However, my analysis suggests that the results provide Cosette with several angles to pursue to bolster its case of a MAC breach. This remains a high-risk/high-reward set-up. 

Shandong Gold Mining Placement – H-Share Running Ahead of A-Shares

By Sumeet Singh

  • Shandong Gold Mining (1787 HK) aims to raise around US$500m via a primary placement, in order to pay down debt.
  • The H-shares are now trading at all-time highs and have been performing better than the A-shares this year.
  • In this note, we talk about the deal dynamics and run the deal through our ECM framework.

Simcere Pharma Placement – First Primary Raising, past Deals Have Been Mixed

By Sumeet Singh

  • Simcere Pharmaceutical Group (2096 HK) is looking to raise around US$200m via a top-up placement.
  • This is the first primary raising by the company since its listing. There have been a few secondary deals, with mixed results.
  • In this note, we talk about the deal dynamics and run the deal through our ECM framework.

HKBN (1310 HK): On the Cusp of Being Declared Unconditional

By Arun George

  • HKBN Ltd (1310 HK)’s offer from China Mobile (941 HK) is HK$5.075 with a 50% minimum acceptance condition. The first closing date is September 3.
  • Based on CCASS data, including acceptances, China Mobile’s shareholding was 48.93% of outstanding shares as of September 1.
  • Therefore, the offer should be declared unconditional by the first closing date. At the last close and for a September 12 payment, the gross/annualised spread is 0.5%/15.7%.

Current Merger Arbitrage Opportunities and Strategic Reviews in Global Markets: Key Active Cases

By Special Situation Investments

  • Apiam Animal Health received a takeover offer at A$0.88/share with an 11% spread, supported by founder Dr. Chris Richards.
  • Plymouth Industrial REIT has a $24.10/share bid from Sixth Street Capital, with a 14-15% spread and board review ongoing.
  • DallasNews has two takeover offers: $15/share from Hearst and $18.5/share from Alden, requiring two-thirds shareholder approval.

Clearing up the FSS’s Sudden Call on Samsung Life’s Samsung Elec Stake Accounting Shift

By Sanghyun Park

  • Today’s FSS IFRS17 ruling is an accounting fix (equity vs. liability), not the Samsung Life Law, which is a regulatory cap on affiliate stakes based on market value.
  • The FSS ruling signals Samsung Life doesn’t need to treat its Samsung Electronics stake as a forced-sale liability, lowering near-term sale risk.
  • This eases the overhang, delays potential stake moves, and reinforces the relative underperformance setup on Samsung C&T highlighted in earlier posts.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars